All formulations manufactured and dispensed from an FDA-Registered Outsourcing Facility must be accompanied with a clinical need. Cost by itself IS NOT considered a clinical need to prescribe or purchase a compound formulation. By agreeing to these terms, you are confirming the purchase of the formulation(s) include one or more of the following clincal need(s):
Pred-Moxi-Nepaf (prednisolone acetate 1%, moxifloxacin 0.5% and nepafenac 0.1%)
- No commercial formulation available.
- Patient has physical and/or mental difficulty with multiple drop regimen.
- Patients cannot tolerate preservatives. Need to reduce exposure to preservatives by 67% or more.
- Reduce the risk of endophthalmitis
- Protect against inflammation.
- Protect against cystoid macular edema.
Pred-Moxi-Brom (prednisolone acetate 1%, moxifloxacin 0.5% and bromfenac 0.075%)
- No commercial formulation available.
- Patients have trouble administering multiple drops.
- Patients cannot tolerate preservatives. Need to reduce exposure to preservatives by 67% or more.
- Reduce the risk of endophthalmitis
- Protect against inflammation.
- Protect against cystoid macular edema.
Pred-Brom (prednisolone acetate 1% and bromfenac 0.075%)*
- Patients have trouble administering multiple drops.
- Need to reduce exposure to preservatives.
- Reduce the risk of endophthalmitis.
- Protect against inflammation.
- Protect against cystoid macular edema.
- No commercial formulation available.
Pred-Acetate 1% PF
- Need to reduce patients exposure to preservatives.
- No commercial preservative free drops available.
- Protect against inflammation.
- Protect against cystoid macular edema.
Tri-Moxi (triamcinolone acetonide 15mg and moxifloxacin hydrochloride 1mg/mL)
- No commercial injectable formulation available.
- Reduce the risk of endophthalmitis.
- Protect against inflammation.
- Protect against cystoid macular edema.
- Patient has physical or mental difficulty with administering topical drop regimen.
- Minimizing the number of times entering the eye to deliver medication to one administration.
Dex-Moxi® (dexamethasone 1mg and moxifloxacin 5mg/mL)
- No commercial injectable formulation available.
- Reduce the risk of endophthalmitis.
- Protect against inflammation.
- Protect against cystoid macular edema.
- Patient has physical or mental difficulty with administering topical drop regimen.
- Minimizing the number of times entering the eye to deliver medication to one administration.
Dex-Moxi-Ketor® (dexamethasone 1mg, moxifloxacin 0.5mg and ketorolac 0.4mg/mL)
- No commercial injectable formulation available.
- Reduce the risk of endophthalmitis.
- Protect against inflammation.
- Protect against cystoid macular edema.
- Patient has physical or mental difficulty with administering topical drop regimen.
- Minimizing the number of times entering the eye to deliver medication to one administration.
Moxifloxacin injectable 0.5% (moxifloxacin 5mg/mL)
- No commercial injectable formulation available.
- Reduce the risk of endophthalmitis.
- Patient has physical or mental difficulty with administering topical drop regimen.
Moxifloxacin injectable 0.1% (moxifloxacin 1mg/mL)
- No commercial injectable formulation available.
- Reduce the risk of endophthalmitis.
- Patient has physical or mental difficulty with administering topical drop regimen.
Phenyl-Lido injectable (phenylephrine 1.5% and lidocaine 1%)
- Combined drops necessary for appropriate dilation.
- Single injection into eye vs. multiple injections.
- Needed as a combined drop for intra-operative floppy iris syndrome (IFIS)
- No combined commercially available product.
- Minimizing the number of times entering the eye to deliver medication to one administration.
Epi-Lido (Lidocaine 0.75% and epinephrine in BSS 0.025%)
- Combined drops necessary for appropriate dilation.
- Single injection into eye vs. multiple injections.
- Needed as a combined drop for intra-operative floppy iris syndrome (IFIS)
- No combined commercially available product.
- Minimizing the number of times entering the eye to deliver medication to one administration.
Klarity-C Drops® Cyclosporine 0.1% (Cyclosporine 0.1% ophthalmic emulsion)
- Need higher strength in emulsion to improve efficacy and minimize irritation.
- No commercially available product at this strength.
- Need to reduce patient exposure to preservatives.
Mydriatic 2 (Tropicamide 1% and phenylephrine 2.5%)
- Combined drops necessary for appropriate dilation.
- No combined commercially available product.
Mydriatic 4 (Tropicamide 1%, proparacaine 0.5%, phenylephrine 2.5% and ketorolac 0.5%)
- Combined drops necessary for appropriate dilation.
- No combined commercially available product.